The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 19, 2023

Filed:

May. 07, 2021
Applicants:

Saint Louis University, St. Louis, MO (US);

Pontificia Universidad Javeriana, Bogota, CO;

Inventors:

Adriana M. Montaño-Suarez, St. Louis, MO (US);

Angela Catalina Sosa-Molano, Bogota, CO;

Alan Knutsen, Webster Groves, MO (US);

Clifford Bellone, St. Louis, MO (US);

Shunji Tomatsu, Wilmington, DE (US);

Luis Barrera, Bogota, CO;

Assignee:

Saint Louis University, St. Louis, MO (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 38/46 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/465 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); C12Y 301/06004 (2013.01);
Abstract

Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.


Find Patent Forward Citations

Loading…